Literature DB >> 24981711

Features of Epstein-Barr virus reactivation after allogeneic hematopoietic cell transplantation in Korean children living in an area of high seroprevalence against Epstein-Barr virus.

Seung Beom Han1, E Young Bae, Jae Wook Lee, Pil Sang Jang, Dong-Gun Lee, Nack-Gyun Chung, Dae Chul Jeong, Bin Cho, Soon Ju Lee, Jin Han Kang, Hack-Ki Kim.   

Abstract

The present study was conducted to investigate Epstein-Barr virus (EBV) reactivation after hematopoietic cell transplantation (HCT) in Korean children living in an area of a high seroprevalence against EBV and to determine the impact of recipient age on EBV reactivation. Medical records of 248 children and adolescents who had received allogeneic HCT were retrospectively reviewed. The trends of EBV reactivation and post-transplant lymphoproliferative disorders (PTLDs) were evaluated and compared between younger (≤10 years old) and older (11-20 years old) groups. EBV reactivation occurred in 177 cases (71.4 %) and high-level EBV reactivation, defined as a virus DNA titer of 300,000 copies/mL or higher, occurred in 21 cases (8.5 %). PTLD was diagnosed in five cases (2.0 %), and one of these patients died. The EBV reactivation rate was not significantly different between the two age groups; however, high-level reactivation and PTLD were more significantly frequent in the older than in the younger group (P = 0.030 and P = 0.026, respectively). In conclusion, older children and adolescents are more likely to experience high-level EBV reactivation and PTLDs, and higher EBV DNA titers than those previously reported may be a predictor of PTLD in areas with a high seroprevalence against EBV.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24981711     DOI: 10.1007/s12185-014-1613-z

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  35 in total

1.  Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell--depleted SCT.

Authors:  J W van Esser; B van der Holt; E Meijer; H G Niesters; R Trenschel; S F Thijsen; A M van Loon; F Frassoni; A Bacigalupo; U W Schaefer; A D Osterhaus; J W Gratama; B Löwenberg; L F Verdonck; J J Cornelissen
Journal:  Blood       Date:  2001-08-15       Impact factor: 22.113

2.  Reconstitution of the Epstein-Barr virus-specific cytotoxic T-lymphocyte response following T-cell-depleted myeloablative and nonmyeloablative allogeneic stem cell transplantation.

Authors:  Suparno Chakrabarti; Donald W Milligan; Deenan Pillay; Stephen Mackinnon; Kathleen Holder; Narinder Kaur; Dorothy McDonald; Christopher D Fegan; Herman Waldmann; Geoff Hale; Alan Rickinson; Neil Steven
Journal:  Blood       Date:  2003-08-01       Impact factor: 22.113

3.  Prevalence of Epstein-Barr virus in Japan: trends and future prediction.

Authors:  Kengo Takeuchi; Keiko Tanaka-Taya; Yukumasa Kazuyama; Yoichi M Ito; Shuji Hashimoto; Masashi Fukayama; Shigeo Mori
Journal:  Pathol Int       Date:  2006-03       Impact factor: 2.534

Review 4.  How I treat EBV lymphoproliferation.

Authors:  Helen E Heslop
Journal:  Blood       Date:  2009-09-01       Impact factor: 22.113

5.  High incidence of post transplant lymphoproliferative disorder after antithymocyte globulin-based conditioning and ineffective prediction by day 28 EBV-specific T lymphocyte counts.

Authors:  M Hoegh-Petersen; D Goodyear; M N Geddes; S Liu; A Ugarte-Torres; Y Liu; J T Walker; K Fonseca; A Daly; P Duggan; D Stewart; J A Russell; J Storek
Journal:  Bone Marrow Transplant       Date:  2010-11-08       Impact factor: 5.483

Review 6.  Progress and problems in understanding and managing primary Epstein-Barr virus infections.

Authors:  Oludare A Odumade; Kristin A Hogquist; Henry H Balfour
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

Review 7.  Epstein-Barr virus load monitoring: its role in the prevention and management of post-transplant lymphoproliferative disease.

Authors:  D T Rowe; S Webber; E M Schauer; J Reyes; M Green
Journal:  Transpl Infect Dis       Date:  2001-06       Impact factor: 2.228

8.  Clinical characteristics and outcomes of posttransplant lymphoproliferative disorders following allogeneic hematopoietic stem cell transplantation in Korea.

Authors:  Sun Hee Park; Su Mi Choi; Dong Gun Lee; Jung Hyun Choi; Jin Hong Yoo; Hee Je Kim; Dong Wook Kim; Jong Wook Lee; Woo Sung Min; Wan Shik Shin; Chun Choo Kim
Journal:  J Korean Med Sci       Date:  2006-04       Impact factor: 2.153

Review 9.  Cytomegalovirus infection after bone marrow transplantation in children.

Authors:  Elio Castagnola; Barbara Cappelli; Daniela Erba; Anna Rabagliati; Edoardo Lanino; Giorgio Dini
Journal:  Hum Immunol       Date:  2004-05       Impact factor: 2.850

10.  Epstein-Barr virus reactivation in allogeneic stem cell transplantation is highly related to cytomegalovirus reactivation.

Authors:  Francesco Zallio; Valeria Primon; Stefania Tamiazzo; Massimo Pini; Anna Baraldi; Maria T Corsetti; Franca Gotta; Claudia Bertassello; Flavia Salvi; Andrea Rocchetti; Alessandro Levis
Journal:  Clin Transplant       Date:  2013-06-19       Impact factor: 2.863

View more
  5 in total

1.  Outcomes of haploidentical bone marrow transplantation in patients with severe aplastic anemia-II that progressed from non-severe acquired aplastic anemia.

Authors:  Hongchen Liu; Xiaoli Zheng; Chengtao Zhang; Jiajun Xie; Beibei Gao; Jing Shao; Yan Yang; Hengxiang Wang; Jinsong Yan
Journal:  Front Med       Date:  2021-06-25       Impact factor: 4.592

Review 2.  Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines.

Authors:  Jan Styczynski; Walter van der Velden; Christopher P Fox; Dan Engelhard; Rafael de la Camara; Catherine Cordonnier; Per Ljungman
Journal:  Haematologica       Date:  2016-07       Impact factor: 9.941

3.  Varicella zoster virus infection after allogeneic hematopoietic cell transplantation in children using a relatively short duration of acyclovir prophylaxis: A retrospective study.

Authors:  Seung Beom Han; Seong Koo Kim; Jae Wook Lee; Dong-Gun Lee; Nack-Gyun Chung; Dae Chul Jeong; Bin Cho; Jin-Han Kang
Journal:  Medicine (Baltimore)       Date:  2017-04       Impact factor: 1.889

4.  Epstein-Barr virus reactivation after allogeneic hematopoietic stem cell transplantation: multifactorial impact on transplant outcomes.

Authors:  Yuhua Ru; Xiang Zhang; Tiemei Song; Yiyang Ding; Ziling Zhu; Yi Fan; Yang Xu; Aining Sun; Huiying Qiu; Zhengming Jin; Xiaowen Tang; Yue Han; Zhengzheng Fu; Suning Chen; Xiao Ma; Feng Chen; Jia Chen; Depei Wu
Journal:  Bone Marrow Transplant       Date:  2020-02-17       Impact factor: 5.483

Review 5.  Factors Associated with Post-Transplant Active Epstein-Barr Virus Infection and Lymphoproliferative Disease in Hematopoietic Stem Cell Transplant Recipients: A Systematic Review and Meta-Analysis.

Authors:  Pascal Roland Enok Bonong; Monica Zahreddine; Chantal Buteau; Michel Duval; Louise Laporte; Jacques Lacroix; Caroline Alfieri; Helen Trottier
Journal:  Vaccines (Basel)       Date:  2021-03-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.